Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5Phase EARLY_PHASE1 2Phase NA 1Phase 4 1Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Genitourinary 14Gastrointestinal 11CNS 10Thoracic 9Breast 8Gynecologic 7Dermatologic 6Plasma cell 5Sarcoma 4Tumor-Agnostic 2Other hematologic neoplasm 2Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1

Conditions

Paraganglioma 1Neuroendocrine Tumors 1Neuroblastoma 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 3surufatinib 2pembrolizumab 2olaparib 2lanreotide 2atezolizumab 2Everolimus 23-Iodobenzylguanidine 2tivozanib 1tislelizumab 1repotrectinib 1regorafenib 1pralsetinib 1irinotecan sucrosofate 1cabozantinib 1avelumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1Tirapazamine 1Temozolomide 1TKM-080301 1S 1 (combination) 1Radiotherapy 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1PM 01183 1Ondansetron 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Magnetic Resonance Spectroscopy × NET × Clear all
NCT02177773 2019-11-12

DOTA-TOC

University of California, San Francisco

Phase 1/2 Terminated
300 enrolled 5 charts
CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡